Investing.com - Can Fite Biopharma ADR reported on Monday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Can Fite Biopharma ADR announced earnings per share of $-0.235 on revenue of $500K. Analysts polled by Investing.com anticipated EPS of $-0.275 on revenue of $250K.
Can Fite Biopharma ADR shares are down 42.12% from the beginning of the year and are trading at $1.910 , down-from-52-week-high.They are under-performing the EUR/USD which is down 0% from the start of the year.
Can Fite Biopharma ADR follows other major sector earnings this month
Can Fite Biopharma ADR's report follows an earnings beat by Tencent ADR on November 12, who reported EPS of $3.31 on revenue of $125.4B, compared to forecasts EPS of $0.47 on revenue of $18.26B.
SoftBank Group had beat expectations on November 9 with third quarter EPS of $1.59 on revenue of $11.22B, compared to forecast for EPS of $0.1297 on revenue of $14.26B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar